Haematemesis during oral aminophylline treatment

Mackay, A.D.; Ramsay, LE; Eppel, M. L.; Oliver, J.S.

doi:10.1136/pgmj.55.644.409

Cited by 9 publications

(3 citation statements)

References 4 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vomiting was accompanied by nausea and malaise, and was not related to tablet ingestion. Two patients had haematemeses, and are described in detail elsewhere (Mackay, Ramsay, Eppel & Oliver, 1979). Patient 9 developed a severe confusional state when the dose was increased to 900 mg daily, and recovered about 24 h after the drug was discontinued.…”

Section: Discussionmentioning

confidence: 98%

Oral sustained‐release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Ramsay¹,

Mackay²,

Eppel³

et al. 1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Consecutive medical inpatients expected to benefit from a theophyllinate were treated with sustained-release aminophylline in a protocol conforming with ordinary practice. Of 16 patients, five had toxicity with aminophylline 450 mg daily, and a further three with 900 mg daily. Toxicity was serious in three patients. 2 Toxicity was significantly less common in cigarette smokers, and was related to higher plasma theophylline concentrations. However, there was a large overlap between concentrations associated with toxicity (as low as 9 pg/ml) and the accepted therapeutic range (5-20 pg/ml). Most patients with toxicity had theophylline levels within the therapeutic range. 3 For the same dose of aminophylline there was sevenfold variation between patients in plasma theophylline, with higher conentrations in non-smokers, infrequent alcohol users, older patients, those with left ventricular failure and those with lower serum transaminases. These variables could not be separated completely because of the small number of observations. 4 A nomogram for aminophylline dosage or monitoring of serum theophylline levels would have prevented little of the toxicity observed in these patients, although these measures would ensure that therapeutic concentrations were attained, and might prevent life-threatening toxicity.

show abstract

Section: Discussionmentioning

confidence: 98%

Oral sustained‐release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Ramsay¹,

Mackay²,

Eppel³

et al. 1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Teofilinin ayrıca hipokalemiye neden olduğu bildirilmiştir [40]. Oral yoldan sürekli salınım yapan aminofilin ile tedavi olan iki hastada hematemez geliştiği bildirilmiştir [43]. Bir diğer vakada teofilin kullanımına bağlı üriner retansiyon bildirilmiştir [44].…”

Section: Teofilin Toksisitesi Teofilinin Ters Etkileriunclassified

“…Teofilin bildirilmiştir [40]. Oral yo lin ile tedavi olan iki hasta [43]. Bir diğer vakada teofil bildirilmiştir [44].…”

Section: Teofilin Toksisitesi Teofilinin Ters Etkileriunclassified

Theophyllıne: Adverse Effects, Poisoning and Treatment Approaches

Charehsaz¹

2011

Ann Clin Anal Med

View full text Add to dashboard Cite

Metilksantin türevi bir bileşik olan teofilin, tüm dünyada ucuz ve etkili olması nedeniyle astım ve kronik obstrüktif akciğer hastalığı (KOAH) tedavisinde yıllardan bu yana yaygın kullanılan bir ilaçtır. Teofilinin kan düzeyleri ile bronkodilatör etkisi arasında yakın bir ilişki vardır. Maksimum bronkodilatör etki elde etmek için kan düzeylerinin 10-20 µg/ml arasında bulunması önemlidir. Dar terapötik aralığa sahip olmasının yanı sıra birçok ilaç, diyet ve sigara, alkol gibi alışkanlıklar ile bireysel faktörlere bağlı olarak farmakokinetik özelliklerinin değişimi, her yaş grubu için çok daha dikkatli kullanımının gerekliliğine yol açmıştır. Sunulan bu derleme yazıda, teofilinin farmakokinetik/dinamik özelliklerine ilaveten zıt etkileri ve aşırı doz teofilin ile zehirlenmeler ve tedavi yaklaşımları verilmiştir.

show abstract

Lack of influence of an intensive antacid regimen on theophylline bioavailability

Reed

Schwartz

1984

Journal of Pharmacokinetics and Biopharmaceutics

View full text Add to dashboard Cite

We examined the influence of a large-volume, therapeutic antacid regimen, administered for three full days, on the steady-state bioavailability of a conventional-release and sustained-release theophylline product, Aminophyllin and Theodur, respectively. Nine stable asthmatics voluntarily completed a four-phase investigation requiring a total stay of 12 days in the Clinical Research Unit. The treatments consisted of administration of the formulations mentioned with and without antacids to each patient in a randomized sequence. Four patients participated in an additional phase where antacids were administered q2h around the clock for three days. After coadministration of theophylline plus antacids for two days, theophylline therapy was discontinued while numerous blood samples were obtained over 22 hr and analyzed for theophylline content via radioimmunoassay. Antacids had no predictable, consistent influence on theophylline absorption rate as determined by the absorption rate constant, the time to maximal theophylline concentration, or the lag time for theophylline absorption. Antacids had no detectable influence on theophylline elimination half-life and had no consistent, statistically significant effect on the extent of theophylline bioavailability, according to measurements of maximal concentration, AUC measured over the appropriate steady-state dosing interval, or elimination-rate adjusted AUC. The substantial intraindividual changes for all parameters of theophylline bioavailability that occurred for control and treatment phases likely represent spontaneous, random between-day variability in theophylline disposition independent of antacid administration, as evidenced by the comparability of the percent coefficient of variation for parameters of bioavailability across all phases. Our data demonstrate that therapeutic antacid administration has no effect on steady-state theophylline bioavailability and does not alter the intrinsic variability in theophylline absorption. Based on the results of our data, it is unlikely that a clinically significant (greater than 20%) decrease in theophylline absorption would occur in any patient treated intensively with antacids concurrently.

show abstract

Haematemesis during oral aminophylline treatment

Abstract: SummaryTwo cases of gastrointestinal bleeding in patients being treated with continuous-release aminophylline tablets are reported.

Cited by 9 publications

References 4 publications

Oral sustained‐release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Oral sustained‐release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Theophyllıne: Adverse Effects, Poisoning and Treatment Approaches

Lack of influence of an intensive antacid regimen on theophylline bioavailability

Contact Info

Product

Resources

About